What are the treatment options for osteopenia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2025 • View editorial policy

From the Guidelines

Osteopenia treatment should prioritize lifestyle modifications, including regular weight-bearing exercise, adequate calcium intake, and vitamin D supplementation, with medication considered for those at higher fracture risk, particularly bisphosphonates like alendronate or risedronate, as recommended by the American College of Physicians 1. The primary approach to treating osteopenia includes:

  • Regular weight-bearing exercise, such as walking, jogging, or resistance training, for 30 minutes most days of the week
  • Adequate calcium intake of 1,000-1,200 mg daily, obtained through dietary sources like dairy products, leafy greens, and fortified foods, or supplements
  • Vitamin D supplementation of 800-1,000 IU daily, which can be obtained through sunlight exposure, supplements, or fortified foods
  • Smoking cessation and limiting alcohol consumption to no more than 1-2 drinks daily For those at higher fracture risk, medications may be prescribed, including:
  • Bisphosphonates like alendronate (Fosamax, 70 mg weekly) or risedronate (Actonel, 35 mg weekly), which work by slowing bone breakdown and allowing bone-building cells to work more effectively 1
  • Other medications like denosumab, teriparatide, or raloxifene may be considered in specific cases, but bisphosphonates are generally preferred due to their safety, cost, and lack of evidence of superior antifracture benefits from other osteoporosis medications 2 Regular bone density testing every 1-2 years is recommended to monitor treatment effectiveness, and fall prevention strategies, such as removing tripping hazards at home and improving balance through exercises like tai chi, are also crucial components of comprehensive osteopenia management. Key considerations for treatment include:
  • Patient preferences and fracture risk profile, as recommended by the American College of Physicians 1
  • Benefits, harms, and costs of medications, as well as potential interactions with other medications or health conditions
  • Lifestyle modifications and non-pharmacologic interventions, such as exercise and fall prevention strategies, which can help reduce fracture risk and improve overall health.

From the FDA Drug Label

Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled during bone turnover Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. Daily oral doses of alendronate (5, 20, and 40 mg for six weeks) in postmenopausal women produced biochemical changes indicative of dose-dependent inhibition of bone resorption, including decreases in urinary calcium and urinary markers of bone collagen degradation Long-term treatment of osteoporosis with alendronate sodium 10 mg/day (for up to five years) reduced urinary excretion of markers of bone resorption

Treatment for Osteopenia:

  • Alendronate sodium 10 mg/day can be used for the treatment of osteoporosis, which is characterized by low bone mass and increased risk of fracture.
  • Alendronate reduces bone resorption and increases bone mass, which can help to prevent fractures.
  • The treatment should be used under the guidance of a healthcare provider, and patients should be monitored for any adverse effects.
  • It is essential to ensure adequate calcium and vitamin D intake during treatment with alendronate sodium.
  • The use of alendronate sodium for the treatment of osteopenia is not explicitly stated in the provided drug labels, but it can be inferred that it may be used to prevent the progression of osteopenia to osteoporosis. 3

From the Research

Treatment Options for Osteopenia

  • The treatment of osteopenia is not always straightforward, and the decision to treat depends on various factors, including the patient's fracture risk and medical history 4.
  • Anti-osteoporotic medication is not always recommended for patients with osteopenia, as the number needed to treat is high (NNT>100) compared to patients with osteoporosis (NNT 10-20) 4.
  • Treatment is usually considered for patients with osteopenia who have a high risk of fracture, such as those with vertebral fractures or a history of low-energy fractures 4, 5.

Non-Pharmacological Interventions

  • Correction of calcium and vitamin D deficiency, as well as regular exercise, such as walking 3 to 5 miles a week, can help improve bone density in patients with osteopenia 6.
  • Adequate intake of protein (1.2-1.5 g/kg/day), vitamin D (800 IU/day), and calcium (1000-1200 mg/day) can help mitigate osteosarcopenia and reduce fracture risk 7.
  • Weight-bearing and resistance-training exercise, as well as fall prevention, are also important components of osteoporosis prevention and treatment 8.

Pharmacological Interventions

  • Antiresorptive treatments, such as hormone replacement therapy, selective estrogen receptor modulators (SERMs), bisphosphonates, and Denosumab, are commonly used to treat osteopenia and osteoporosis 4, 6.
  • Anabolic therapy may be considered for patients with osteoporosis who have failed anti-resorptive therapy 6.
  • Current medications for osteoporosis can build bone and/or decrease bone breakdown, and dramatically reduce incident fractures, but do not cure the disease 8.

References

Research

Treatment of osteopenia.

Reviews in endocrine & metabolic disorders, 2012

Research

Osteopenia: a diagnostic and therapeutic challenge.

Current osteoporosis reports, 2011

Research

Diagnosis and treatment of osteopenia.

Reviews in endocrine & metabolic disorders, 2010

Research

Nutrients to mitigate osteosarcopenia: the role of protein, vitamin D and calcium.

Current opinion in clinical nutrition and metabolic care, 2021

Research

The clinician's guide to prevention and treatment of osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2022

Related Questions

Do any of these medications treat or worsen osteopenia: Glucagon (Glucagon (recombinant DNA)) Emergency Injection Kit, Milk of Magnesia (Magnesium Hydroxide) Concentrate Suspension, Colestid (Colestipol Hydrochloride) Oral Tablet, Glucose (Dextrose) Oral Gel, Pregabalin Oral Capsule, Acetaminophen (Paracetamol) Tablet, Clonazepam (Clonazepam) Oral Tablet, Probiotic (Saccharomyces boulardii) Oral Capsule, Sodium Bicarbonate (Sodium Bicarbonate) Oral Tablet, Lamotrigine (Lamotrigine) Oral Tablet, Ventolin (Albuterol Sulfate) HFA Inhalation Aerosol Solution, Flonase (Fluticasone Propionate) Allergy Relief Nasal Suspension, Symbicort (Budesonide-Formoterol Fumarate Dihydrate) Inhalation Aerosol, Torsemide (Torsemide) Oral Tablet, Lovenox (Enoxaparin Sodium) Injection Solution, Ipratropium-Albuterol (Ipratropium Bromide-Albuterol Sulfate) Inhalation Solution, Synthroid (Levothyroxine Sodium) Oral Tablet, Humalog (Insulin Lispro) Injection Solution, Cyanocobalamin (Cyanocobalamin) Injection Kit, Robaxin (Methocarbamol) Oral Tablet, Lantus (Insulin Glargine) SoloStar Subcutaneous Solution Pen-injector, Loperamide (Loperamide Hydrochloride) Oral Tablet, Creon (Pancrelipase) Oral Capsule, Melatonin (Melatonin) Oral Tablet?
What is the diagnosis and treatment plan for a 73-year-old female with osteopenia, presenting with a T score of -1.7 in the spine and -2.0 in the hip, indicating osteoporosis (bone mineral density loss)?
What is the recommended frequency for Dual-Energy X-ray Absorptiometry (DEXA) scans in individuals with osteopenia?
What is the recommended duration to discontinue Alendronate (bisphosphonate) in patients with osteopenia?
Is calcium helpful for osteopenia?
Is doxycycline (Doxycycline) effective for treating cellulitis?
What diseases present with blepharospasm (involuntary hard blinking)?
What is the recommended time frame to recheck lipid profiles after initiating statin (HMG-CoA reductase inhibitor) therapy?
What is the most appropriate management for a patient with IBD, presenting with abdominal pain, bilious vomiting, and a stricture at the terminal ileum?
How do you describe difficulty hearing lung sounds due to obesity?
What is the differential diagnosis (Ddx) for hypopigmentation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.